INDBInternet News Database 2.5 Updated 1 min ago · 297 sources Show or hide images Light or dark

Results for “Novo's Wegovy”

Health
2 sources

Who is covering this

ReutersCenterAmherst BeeNot rated
Truth score 57
Centre 100%100%
ReutersCenter

Lilly says its obesity drugs helped patients lose weight in clinical trials

Lilly says its obesity drugs helped patients lose weight in clinical trials Reuters

Lean: Center Fact-focusedFactuality: Very highCountry: United KingdomFunding: CorporateOwner: Thomson Reuters
+ 1 · Full coverage
Coverage breakdown
Funding
Corporate50%
Not recorded50%
Countries
United Kingdom50%
United States50%
Media ownership
Thomson Reuters50%
Amherst Bee50%
Avg reliability92
Low-credibility share0%
Fact / opinion3/0
State media0%
More analysis
Truth score: 57 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 2 Reliability: 92 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Health
2 sources

Who is covering this

ReutersCenterYahoo NewsCenter
Truth score 531
Centre 100%100%
ReutersCenter

Novo Nordisk's Wegovy pill beats forecasts as it battles Lilly

Novo Nordisk's Wegovy pill beats forecasts as it battles Lilly Reuters

Lean: Center Fact-focusedFactuality: Very highCountry: United KingdomFunding: CorporateOwner: Thomson Reuters
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United Kingdom50%
United States50%
Media ownership
Thomson Reuters50%
Apollo Global Management50%
Avg reliability81
Low-credibility share0%
Fact / opinion2/0
State media0%
More analysis
Truth score: 53 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 2 Reliability: 81 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Left 46%46%Centre 42%42%Right 12%12%
BBC NewsCenter

Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness

The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION. Companies making popular weight loss drugs, including Ozempic and Wegovy, will be required to...

Lean: Center Fact-focusedFactuality: Very highCountry: United KingdomFunding: Public broadcasterOwner: BBC (UK Government)
+ 37 · Full coverage
Coverage breakdown
Funding
Corporate62%
Not recorded17%
Public broadcaster7%
Private7%
Nonprofit3%
Countries
United States76%
India14%
United Kingdom10%
Media ownership
Independent19%
Comcast12%
G/O Media12%
WSNS-TV6%
Google News6%
Avg reliability74
Low-credibility share4%
Fact / opinion42/0
State media0%
More analysis
Truth score: 91 (Strongly corroborated) Propaganda risk: 0 Trending: Low Sources: 29 Reliability: 74 Bias severity: 57 Risk: 4Sentiment: -95Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

Amherst BeeNot rated
Truth score 34
No rated outlets yet
Amherst BeeNot rated

Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology

REDEFINE 9 trial showed CagriSema 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg produced estimated average weight loss of 20.7% and 21.0%, respectively, at 68 weeks, compared with 2.0% with placebo, in adults with overweight or obesity,…

Lean: Not rated Fact-focusedCountry: United States
Full coverage
Coverage breakdown
Funding
Not recorded100%
Countries
United States100%
Media ownership
Amherst Bee100%
Avg reliability-
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 34 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: Not rated Bias severity: 0 Risk: 0Sentiment: -100Sensationalism: 8 Amplification: 0

How we score

Like
Business
3 sources
Truth score 58
Centre 100%100%
CNBCCenter

CVS Health plans to split itself up. Here's why a breakup could make sense now

Analysts say that after a roughly two-year turnaround the company's retail pharmacy business and other units may be strong enough to stand on their own. Covered by 3 outlets: 3 are centre.

Lean: Center Fact-focusedFactuality: HighCountry: United StatesFunding: Corporate
+ 1 · Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States67%
India33%
Media ownership
Independent33%
CNBC33%
Google News33%
Avg reliability78
Low-credibility share0%
Fact / opinion4/0
State media0%
More analysis
Truth score: 58 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 3 Reliability: 78 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 8 Amplification: 0

How we score

Like
Left 40%40%Centre 40%40%Right 20%20%
TIMELeans left

Weight-Loss Drugs May Help Sleep Apnea and Arthritis

Eli Lilly reported results from new studies exploring the effects of its GLP-1 weight-loss drugs on sleep apnea and arthritis. China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s...

Lean: Leans left Fact-focusedFactuality: HighCountry: United StatesFunding: CorporateOwner: Marc Benioff
+ 2 · Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States60%
United Kingdom20%
Hong Kong20%
Media ownership
G/O Media20%
Thomson Reuters20%
Marc Benioff20%
Independent20%
Alibaba Group20%
Avg reliability77
Low-credibility share0%
Fact / opinion7/0
State media0%
More analysis
Truth score: 75 (Corroborated) Propaganda risk: 0 Trending: Low Sources: 5 Reliability: 77 Bias severity: 33 Risk: 0Sentiment: -29Sensationalism: 0 Amplification: 0

How we score

Like
Crime and Justice
1 source

Who is covering this

ReutersCenter
Truth score 47
Centre 100%100%
ReutersCenter

Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing

Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing Reuters

Lean: Center Fact-focusedFactuality: Very highCountry: United KingdomFunding: CorporateOwner: Thomson Reuters
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United Kingdom100%
Media ownership
Thomson Reuters100%
Avg reliability92
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 47 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 92 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
1 source

Who is covering this

CNBCCenter
Truth score 43
Centre 100%100%
CNBCCenter

Novo raises full-year outlook as Wegovy pill sales impress

Novo posted quarterly earnings ahead of expectations early Wednesday as sales of its Wegovy pill blew past estimates

Lean: Center Fact-focusedFactuality: HighCountry: United StatesFunding: Corporate
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
CNBC100%
Avg reliability80
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 43 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 80 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Entertainment
1 source

Who is covering this

DeadlineCenter
Truth score 41
Centre 100%100%
DeadlineCenter

Narrative Global Sales Takes Three Genre Films To AFM Including Jenna Kanell Sci-Fi ‘De Novo’ With Lilly Wachowski Aboard

EXCLUSIVE: Lilly Wachowski’s Anarchists United with Sarah Marie Flores and Lawrence Mattis have joined the upcoming sci-fi film De Novo as executive producers. Written and directed by Terrifier actress Jenna Kanell, and currently in...

Lean: Center Fact-focusedFactuality: HighCountry: United StatesFunding: CorporateOwner: Penske Media Corporation
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Penske Media Corporation100%
Avg reliability75
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 41 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 75 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

MedscapeCenter
Truth score 38
Centre 100%100%
MedscapeCenter

DCBs Hold Their Own Against Stents in De Novo Lesions

In noncomplex coronary artery disease, a drug coated-balloon is noninferior to a drug-eluting stent at 12 months.

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

MedpagetodayCenter
Truth score 38
Centre 100%100%
MedpagetodayCenter

Study Strengthens Case for Stent-Free PCI in De Novo Coronary Lesions

(MedPage Today) -- For de novo coronary lesions, drug-coated balloons (DCBs) were just as effective as standard drug-eluting stents, the TRANSFORM II trial showed. Among patients with native coronary lesions undergoing percutaneous...

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Business
1 source

Who is covering this

The GuardianLeft
Truth score 45
Left 100%100%
The GuardianLeft

Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes...

Lean: Left Fact-focusedFactuality: Very highCountry: United KingdomFunding: Nonprofit trustOwner: Scott Trust
Full coverage
Coverage breakdown
Funding
Nonprofit trust100%
Countries
United Kingdom100%
Media ownership
Scott Trust100%
Avg reliability85
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 45 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 85 Bias severity: 0 Risk: 0Sentiment: -100Sensationalism: 0 Amplification: 0

How we score

Like
World
1 source

Who is covering this

The Epoch TimesRight
Truth score 17Factuality: Low
Right 100%100%
The Epoch TimesRight

First Weight-Loss Tablet Approved for Use in Australia

Low reliability sourceElevated risk

A sign bearing the logo of Novo Nordisk next to the company's factory in Hillerod, Denmark, on Nov. 12, 2025. (Sergei Gapon/AFP via Getty Images)

Lean: Right Fact-focusedFactuality: LowCountry: United StatesFunding: PrivateOwner: Epoch Media Group
Full coverage
Coverage breakdown
Funding
Private100%
Countries
United States100%
Media ownership
Epoch Media Group100%
Avg reliability35
Low-credibility share100%
Fact / opinion1/0
State media0%
More analysis
Truth score: 17 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 35 Bias severity: 0 Risk: 100Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Science
1 source

Who is covering this

NatureNo political lean
Truth score 34
No rated outlets yet
NatureNo political lean

China plans ban on biotech exports

Nature Biotechnology, Published online: 10 November 2026; doi:10.1038/s41587-026-03397-6 China plans ban on biotech exports

Lean: No political lean Fact-focusedCountry: United StatesFunding: CorporateOwner: Independent
+ 4 · Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability-
Low-credibility share0%
Fact / opinion5/0
State media0%
More analysis
Truth score: 34 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: Not rated Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like